A Review of Kinases Implicated in Pancreatic Cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Giroux, 2006, Probing the human kinome for kinases involved in pancreatic cancer ceil survival and gemcitabine resistance, FASEB J, 20, 1982, 10.1096/fj.06-6239com
Baselga, 2002, Why the epidermal growth factor receptor? The rationale for cancer therapy, Oncologist, 7, 2, 10.1634/theoncologist.7-suppl_4-2
Herbst, 2002, Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy, Cancer, 94, 1593, 10.1002/cncr.10372
Yarden, 2001, Untangling the ErbB signalling network, Nat Rev Moi Cell Biol, 2, 127, 10.1038/35052073
Mover, 1997, Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase, Cancer Res, 57, 4838
Schlessinger, 2000, Cell signaling by receptor tyrosine kinases, Cell, 103, 211, 10.1016/S0092-8674(00)00114-8
Arteaga, 2001, The epidermal growth factor receptor: from mutant oncogene in non-human cancers to therapeutic target in human neoplasia, J Clin Oncol, 19, 32S
Mendelsohn, 2001, The epidermal growth factor receptor as a target for cancer therapy, Endocr Relat Cancer, 8, 3, 10.1677/erc.0.0080003
Ennis, 1991, The EGF receptor system as a target for antitumor therapy, Cancer Invest, 9, 553, 10.3109/07357909109018953
Ross, 1998, The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy, Stem Cells, 16, 413, 10.1002/stem.160413
Arnoletti, 2004, Mechanisms of resistance to Erbitux (anti-epidermal growth factor receptor) combination therapy in pancreatic adenocarcinoma ceils, J Gastrointest Surg, 8, 960, 10.1016/j.gassur.2004.09.021
Bruns, 2000, Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms, Clin Cancer Res, 6, 1936
Buchsbaum, 2002, Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation, Int J Radiat Oncol Biol Phys, 54, 1180, 10.1016/S0360-3016(02)03788-4
Overholser, 2000, Epidermal growth factor receptor blockade by antibody EMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice, Cancer, 89, 74, 10.1002/1097-0142(20000701)89:1<74::AID-CNCR11>3.0.CO;2-K
Sclabas, 2003, Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-KB signaling pathway with the anti-epidermal growth factor antibody IMC-G225, J Gastrointest Surg, 7, 37, 10.1016/S1091-255X(02)00088-4
Huang, 2003, Differential responses by pancreatic carcinoma cell lines to prolonged exposure to Erbitux (IMC-C225) anti-EGFR antibody, J Surg Res, 111, 274, 10.1016/S0022-4804(03)00076-3
Xiong, 2004, Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial, J Clin Oncol, 22, 2610, 10.1200/JCO.2004.12.040
Novotny, 2001, Prognostic significance of c-ErbB-2 gene expression in pancreatic cancer patients, Neoplasma, 48, 188
Safran, 2004, Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu, Cancer Invest, 22, 706, 10.1081/CNV-200032974
Safran, 2001, Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma, Am J Clin Oncol, 24, 496, 10.1097/00000421-200110000-00016
Saxby, 2005, Assessment of HER-2 status in pancreatic adenocarcinoma; correlation of immunohistochemistry, quantitative real-time RT-PCR, and fish with aneuploidy and survival, Am J Surg Pathol, 29, 1125, 10.1097/01.pas.0000160979.85457.73
Buchler, 2001, Therapy for pancreatic cancer with a recombinant humanized anti-HER2 antibody (Herceptin), J Gastrointest Surg, 5, 139, 10.1016/S1091-255X(01)80025-1
Buchler, 2005, Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy, Int J Oncol, 27, 1125
Yang, 2001, Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy, Crit Rev Oncol Hematol, 38, 17, 10.1016/S1040-8428(00)00134-7
Yang, 1999, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor re- ceptor without concomitant chemotherapy, Cancer Res, 59, 1236
Foon, 2004, Preclinical and clinical evaluations of ABX-EGF, a fully human antiepidermal growth factor receptor antibody, Int J Radiat Oncol Biol Phys, 58, 984, 10.1016/j.ijrobp.2003.09.098
Bangard, 2005, Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits humanpancre-atic carcinoma growth. lut, J Cancer, 114, 131
Graeven, 2006, study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD72000) combined with gemcitabine in advanced pancreatic cancer, Br J Cancer, 94, 1293, 10.1038/sj.bjc.6603083
Cella, 2005, Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial, J Clin Oncol, 23, 2946, 10.1200/JCO.2005.05.153
Thatcher, 2005, Gefitinib plus best supportive care in previously treated patients with refractory advanced non- small-cell lung cancer: Results from a randomised, placebo- controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer), Lancet, 366, 1527, 10.1016/S0140-6736(05)67625-8
Cools, 2005, Resistance to tyrosine kinase inhibitors: calling on extra forces, Drug Resist Updat, 8, 119, 10.1016/j.drup.2005.04.005
Li, 2004, Gefitinib (‘Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation, Int J Oncol, 25, 203
Durkin, 2003, Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro, Am J Surg, 186, 431, 10.1016/j.amjsurg.2003.07.008
Ng, 2002, Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma, Moi Cancer Ther, 1, 777
Moore, 2005, A new combination in the treatment of advanced pancreatic cancer, Semin Oncol, 32, 5, 10.1053/j.seminoncol.2005.07.017
Wissner, 2002, Syntheses and EGFR and HER-2 kinase inhibitory activities of 4-anilinoquinoline-3-carbonitriles: analogues of three important 4-anilinoquinazolines currently undergoing clinical evaluation as therapeutic antitumor agents, Bioorg Med Chem Lett, 12, 2893, 10.1016/S0960-894X(02)00598-X
Baker, 2002, Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer, Cancer Res, 62, 1996
Bruns, 2000, Blockade of the epidermal growth factor receptor signaling by anovel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma, Cancer Res, 60, 2926
Solorzano, 2001, Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, Cancer Biother Radiopharm, 16, 359, 10.1089/108497801753354267
Burris, 2005, Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas, J Clin Oncol, 23, 5305, 10.1200/JCO.2005.16.584
Spector, 2005, Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB land ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies, J Clin Oncol, 23, 2502, 10.1200/JCO.2005.12.157
Burris, 2004, Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib, Oncologist, 9, 10, 10.1634/theoncologist.9-suppl_3-10
Chu, 2005, The dual ErbBl/ErbB2 inhibitor, lapatinib (GW572016), cooperates with tamoxifen to inhibit both cell proliferation- and estrogendependent gene expression in antiestrogen-resistant breast cancer, Cancer Res, 65, 18, 10.1158/0008-5472.18.65.1
Ferrara, 1997, The biology of vascular endothelial growth factor, Endocr Rev, 18, 4, 10.1210/er.18.1.4
Shibuya, 1990, Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (Fit) closely related to the fms family, Qncogene, 5, 519
Terman, 1991, [dentification of a new endothelial cell growth factor receptor tyrosine kinase, Oncogene, 6, 1677
Karkkainen, 2002, Lymphatic endothelium: a new frontier of metastasis research, Nat Cell Biol, 4, E2, 10.1038/ncb0102-e2
Kim, 1993, Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo, Nature, 362, 841, 10.1038/362841a0
Fukumura, 1998, Tumor induction of VEGF promoter activity in stromal cells, Cell, 94, 715, 10.1016/S0092-8674(00)81731-6
Gerber, 2000, Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor, Cancer Res, 60, 6253
Tsuzuki, 2000, Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducibie factor-1α → hypoxia response element → VEGF cascade differentially regulates vascular response and growth rate in tumors, Cancer Res, 60, 6248
Inoue, 2002, VEGF-A has a critical, non-redundant role in angiogenic switching and pancreatic β-cell carcinogenesis, Cancer Cell, 1, 193, 10.1016/S1535-6108(02)00031-4
Bergers, 2000, Matrix metaloproteinase-9 triggers the angiogenic switch during carcinogenesis, Nat Cell Biol, 2, 737, 10.1038/35036374
Zhu, 2003, Inhibition of human leukemia in an animal model with human antibodies directed against vascular endothelial growth factor receptor 2. Correlation between antibody affinity and biological activity, Leukemia, 17, 604, 10.1038/sj.leu.2402831
Posey, 2003, A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from coiorectal carcinoma, Clin Cancer Res, 9, 1323
Prewett, 1999, Antivascuiar endotheiiai growth factor receptor (fetal liver kinase-1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors, Cancer Res, 59, 5209
Bruns, 2002, Effect of the vascular endothelial growth factor receptor-2 antibody DC101 plus gemcitabine on growth, metastasis and angiogenesis of human pancreatic cancer growing or thotopically in nude mice, Int J Cancer, 102, 101, 10.1002/ijc.10681
Solorzano, 2001, Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma, Ciin Cancer Res, 7, 2563
Ryan, 2005, ZD6474 — a novel inhibitor of VEGFR and EGFR tyrosine kinase activity, Br J Cancer, 92, S6, 10.1038/sj.bjc.6602603
Taguchi, 2004, Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib (‘Iressa’)-sensitive and resistant xenograft models, Cancer Sci, 95, 984, 10.1111/j.1349-7006.2004.tb03187.x
Eskens, 2004, Angiogenesis inhibitors in clinical development; where are we now and where are we going, Br J Cancer, 90, 1, 10.1038/sj.bjc.6601401
Fong, 1999, SU5416 is a potent and selective inhibitor of the vascular endotheiiai growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types, Cancer Res, 59, 99
Laird, 2002, SU6668 inhibits Fik-1/ KDR and PDGFRβ in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice, FASEB J, 16, 681, 10.1096/fj.01-0700com
Bergers, 2003, Benefits of targeting both pericytes and endotheiiai ceils in the tumor vasculature with kinase inhibitors, J Clin Invest, 111, 1287, 10.1172/JCI200317929
Bocci, 2004, Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine, Eur J Pharmacol, 498, 9, 10.1016/j.ejphar.2004.07.062
Davis, 2005, Pharmacodynamic analysis of target inhibition and endotheiiai cell death in tumors treated with the vascular en- dothelial growth factor receptor antagonists SU5416 or SU6668, Clin Cancer Res, 11, 678, 10.1158/1078-0432.678.11.2
Griffin, 2002, Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibrobiast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response, Cancer Res, 62, 1702
O'Farrell, 2003, An innovative phase I clinical study demonstrates inhibition of Fit-3 phosphorylation by SU11248 in acute myeioid leukemia patients, Clin Cancer Res, 9, 5465
Wedge, 2000, 2D4190: an orally active inhibitor of vascular endotheiiai growth factor signaling with broad-spectrum antitumor efficacy, Cancer Res, 60, 970
Wedge, 2005, AZD2171: a highly potent, orally bioavailabie, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer, Cancer Res, 65, 4389, 10.1158/0008-5472.CAN-04-4409
Drevs, 2007, Phase I clinical study of AZD2I71, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors, J Clin Oncol, 25, 3045, 10.1200/JCO.2006.07.2066
Ruggeri, 2003, CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models, Cancer Res, 63, 5978
Inai, 2004, Inhibition of vascular endothelial growth factor signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts, Am J Pathol, 165, 35, 10.1016/S0002-9440(10)63273-7
Rugo, 2005, Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results, J Clin Oncol, 23, 5474, 10.1200/JCO.2005.04.192
Bergsten, 2001, PDGF-D is a specific, protease-activated ligand for the PDGF β-receptor, Nat Cell Biol, 3, 512, 10.1038/35074588
Fredriksson, 2004, The PDGF family: four gene products form five dimeric isoforms, Cytokine Growth Factor Rev, 15, 197, 10.1016/j.cytogfr.2004.03.007
Li, 2000, PDGF-C is a new protease-activated ligand for the PDGF α-receptor, Nat Cell Biol, 2, 302, 10.1038/35010579
Betsholtz, 1986, CDNA sequence and chromosomal localization of human platelet-derived growth factor α-chain and its expression in tumour cell lines, Nature, 320, 695, 10.1038/320695a0
Uutela, 2001, Chromosomal location, exon structure, and vascular expression patterns of the human PDGFC and PDGFC genes, Circulation, 103, 2242, 10.1161/01.CIR.103.18.2242
Tallquist, 2004, PDGF signaling in cells and mice, Cytokine Growth Factor Rev, 15, 205, 10.1016/j.cytogfr.2004.03.003
Heidaran, 1993, Differences in substrate specificities of α-and β-platelet- derived growth factor (PDGF) receptors, Correlation with their ability to mediate PDGF transforming functions. J Biol Chem, 268, 9287
Raines, 2004, PDGF and cardiovascular disease, Cytokine Growth Factor Rev, 15, 237, 10.1016/j.cytogfr.2004.03.004
Bonner, 2004, Regulation of PDGF and its receptors infibrotic diseases, Cytokine Growth Factor Rev, 15, 255, 10.1016/j.cytogfr.2004.03.006
Pietras, 2003, PDGF receptors as cancer drug targets, Cancer Cell, 3, 439, 10.1016/S1535-6108(03)00089-8
Hermanson, 1992, Platelet-derived growth factor and its recep tors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops, Cancer Res, 52, 3213
Dabrow, 1998, The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium, Gynecol Oncol, 71, 29, 10.1006/gyno.1998.5121
Fudge, 1994, Immunohistochemistry analysis of platelet-derived growth factor a and b chains and platelet-derived growth factor α- and β-receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas, Mod Pathol, 7, 549
Pietras, 2001, Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors, Cancer Res, 1, 2929
Pietras, 2005, Amultitargeted, metronomic, and maximum-tolerated dose ‘chemo-switch’ regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer, J Clin Oncol, 23, 939, 10.1200/JCO.2005.07.093
Farivar, 2003, The efficacy of tyrosine kinase inhibitors on human pancreatic cancer cell lines, J Surg Res, 115, 219, 10.1016/S0022-4804(03)00246-4
Li, 2003, Effects of STI571 (Gleevec) on pancreatic cancer cell growth, Mol Cancer, 2, 32, 10.1186/1476-4598-2-32
Hwang, 2003, Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model, Clin Cancer Res, 9, 6534
Chen, 2006, The tyrosine kinase inhibitor imatinib fails to inhibit pancreatic cancer progression, Cancer Lett, 233, 328, 10.1016/j.canlet.2005.03.027
Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443
Ahmad, 2004, Kinase inhibition with BAY 43-9006 in renal cell carcinoma, Clin Cancer Res, 10, 63885, 10.1158/1078-0432.CCR-040028
Awada, 2005, Phase I safety and pharmacokinetics of BAY43-9006 admimstered for 21 days on/7 days off in patients with advanced, refractory solid tumours, Br J Cancer, 92, 1855, 10.1038/sj.bjc.6602584
Richly, 2004, Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer, Int J Clin Pharmacol Ther, 42, 650, 10.5414/CPP42650
Ko, 2001, A multi-institutional phase ii study of SU 101, a platelet-derived growth factor receptor inhibitor, for patients with hormone-refractory prostate cancer, Clin Cancer Res, 7, 800
Thomas, 1997, Cellular functions regulated by Src family kinases, Annu Rev Cell Dev Biol, 13, 513, 10.1146/annurev.cellbio.13.1.513
Toyoshima, 1987, Viral oncogenes, v-Yes and v-ErbB, and their cellular counterparts, Adv Virus Res, 32, 97, 10.1016/S0065-3527(08)60475-3
Frame, 2002, Src in cancer: deregulation and consequences for cell behaviour, Biochim Biophys Acta, 1602, 114
Sicheri, 1997, Crystal structure of the Src family tyrosine kinase Hck, Nature, 385, 602, 10.1038/385602a0
Xu, 1997, Three-dimensional structure of the tyrosine kinase c-Src, Nature, 385, 595, 10.1038/385595a0
Cartwright, 1987, Cell transformation by pp60c-src mutated in the carboxy-terminal regulatory domain, Cell, 49, 83, 10.1016/0092-8674(87)90758-6
Kmiecik, 1987, Activation and suppression of pp60c-srctransforming ability by mutation of its primary sites of tyrosine phosphoryiation, Cell, 49, 65, 10.1016/0092-8674(87)90756-2
Piwnica-Worms, 1987, Tyrosine phosphoryiation regulates the biochemical and biological properties of pp60c-src, Cell, 49, 75, 10.1016/0092-8674(87)90757-4
Irby, 1999, Activating SRC mutation in a subset of advanced human colon cancers, Nat Genet, 21, 187, 10.1038/5971
Brown, 1996, Regulation, substrates and functions of src, Biochim Biophys Acta, 1287, 121
Irby, 2000, Role of Src expression and activation in human cancer, Oncogene, 19, 5636, 10.1038/sj.onc.1203912
Ito, 2003, Inhibition of tyrosine kinase Src suppresses pancreatic cancer invasiveness, Surgery, 134, 221, 10.1067/msy.2003.224
Duxbury, 2004, Inhibition of Src tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells, Clin Cancer Res, 10, 2307, 10.1158/1078-0432.CCR-1183-3
Yezhelyev, 2004, Inhibition of Srctyrosine kinase as treatment for human pancreatic cancer growing orthotopically in nude mice, Clin Cancer Res, 10, 8028, 10.1158/1078-0432.CCR-04-0621
Brose, 2002, BRAF and RAS mutations in human lung cancer and melanoma, Cancer Res, 62, 6997
Calhoun, 2003, BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets, Am J Pathol, 163, 1255, 10.1016/S0002-9440(10)63485-2
Ishimura, 2003, BRAF and K-ras gene mutations in human pancreatic cancers, Cancer Lett, 199, 169, 10.1016/S0304-3835(03)00384-7
Mercer, 2003, Raf proteins and cancer: B-Raf is identified as a mutational target, Biochim Biophys Acta, 1653, 25
Chang, 2003, Signal transduction mediated by the RAS/RAF/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention, Leukemia, 17, 1263, 10.1038/sj.leu.2402945
Milella, 2001, Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia, J Clin invest, 108, 851, 10.1172/JCI12807
Pruitt, 2001, Ras and rho regulation of the cell cycle and oncogenesis, Cancer Lett, 171, 1, 10.1016/S0304-3835(01)00528-6
Mirza, 2004, Cooperative regulation of the cell division cycle by the protein kinases RAF and AKT, Mol Cell Biol, 24, 10868, 10.1128/MCB.24.24.10868-10881.2004
Roovers, 2000, Integrating the MAP kinase signal into the G1 phase cell cycle machinery, Bioessays, 22, 818, 10.1002/1521-1878(200009)22:9<818::AID-BIES7>3.0.CO;2-6
Zhu, 1998, Senescence of human fibroblasts induced by oncogenic Raf, Genes Dev, 12, 2997, 10.1101/gad.12.19.2997
Dudley, 1995, A synthetic inhibitor of the mitogen-activated protein kinase cascade, Proc Natl Acad Sci USA, 92, 7686, 10.1073/pnas.92.17.7686
English, 2002, Pharmacological inhibitors of MAPK pathways, Trends Pharmacol Sci, 23, 40, 10.1016/S0165-6147(00)01865-4
Favata, 1998, Identification of a novel inhibitor of mitogen-activated protein kinase kinase, J Biol Chem, 273, 18623, 10.1074/jbc.273.29.18623
Ohren, 2004, Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition, Nat Struct Mol Biol, 11, 1192, 10.1038/nsmb859
Sebolt-Leopold, 1999, Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo, Nat Med, 5, 810, 10.1038/10533
Gysin, 2005, Pharmacologie inhibition of RAF → MEK → ERK signaling elicits pancreatic cancer cell cycle arrest through induced expression of p27Kipl, Cancer Res, 65, 4870, 10.1158/0008-5472.CAN-04-2848
Yip-Schneider, 2003, MEK inhibition of pancreatic carcinoma cells by U0126 and its effect in combination with sulindac, Pancreas, 27, 337, 10.1097/00006676-200311000-00012
Cantley, 2002, The phosphoinositide 3-kinase pathway, Science, 296, 1655, 10.1126/science.296.5573.1655
Alessi, 1996, Mechanism of activation of protein kinase B by insulin and IGF-1, EMBO J, 15, 6541, 10.1002/j.1460-2075.1996.tb01045.x
Bondar, 2002, Inhibition of the phosphatidylinositol 3'-kinase-AKT pathway induces apoptosis in pancreatic carcinoma cells in vitro and in vivo, Mol Cancer Ther, 1, 989
Yip-Schneider, 2001, Cell cycle effects of nonsteroidal anti-inflammatory drugs and enhanced growth inhibition in combination with gemcitabine in pancreatic carcinoma cells, J Pharmacol Exp Ther, 298, 976
Ke, 2003, Function and regulation of aurora/Ipl1p kinase family in cell division, Ceil Res, 13, 69, 10.1038/sj.cr.7290152
Anand, 2003, Aurora-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to taxol, Cancer Cell, 3, 51, 10.1016/S1535-6108(02)00235-0
Katayama, 2004, Phosphorylation by aurora kinase a induces MDM2-mediated de stabilization and inhibition of p53, Nat Genet, 36, 55, 10.1038/ng1279
Furukawa, 2006, Aurka is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer, Oncogene, 25, 4831, 10.1038/sj.onc.1209494
Woodgett, 1990, Molecular cloning and expression of glycogen synthase kinase-3/factor A, EMBO J, 9, 2431, 10.1002/j.1460-2075.1990.tb07419.x
Doble, 2003, GSK-3: tricks of the trade for a multi-tasking kinase, J Cell Sci, 116, 1175, 10.1242/jcs.00384
Rubinfeld, 1996, Binding of GSK-3β to the APC-β-catenin complex and regulation of complex assembly, Science, 272, 1023, 10.1126/science.272.5264.1023
Hoeflich, 2000, Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation, Nature, 406, 86, 10.1038/35017574
Demarchi, 2003, Glycogen synthase kinase-3β regulates Nf-KB1/p105 stability, J Biol Chem, 278, 39583, 10.1074/jbc.M305676200
Ougolkov, 2006, Aberrant nuclear accumulation of glycogen synthase kinase-3β in human pancreatic cancer: association with kinase activity and tumor dedifferentiation, Clin Cancer Res, 12, 5074, 10.1158/1078-0432.CCR-06-0196
Shakoori, 2005, Deregulated GSK-3β activity in colorectal cancer: its association with tumor cell survival and proliferation, Biochem Biophys Res Commun, 334, 1365, 10.1016/j.bbrc.2005.07.041
Nishizuka, 1995, Protein kinase C and lipid signaling for sustained cellular responses, FASEB J, 9, 484, 10.1096/fasebj.9.7.7737456
Parekh, 2000, Multiple pathways control protein kinase C phosphorylation, EMBO J, 19, 496, 10.1093/emboj/19.4.496
Newton, 2001, structural and spatial regulation byphosphorylation, cofactors, and macromolecular interactions, Chem Rev, 101, 2353, 10.1021/cr0002801
Baier, 2003, The PKC gene module; molecular biosystematics to resolve its T-cell functions, Immunol Rev, 192, 64, 10.1034/j.1600-065X.2003.00018.x
Mandil, 2001, Protein kinase Cα and protein kinase Cδplay opposite roles in the proliferation and apoptosis of glioma cells, Cancer Res, 61, 4612
Ways, 1995, MCF-7 breast cancer cells transfected with protein kinase Cα exhibit altered expression of other protein kinase C isoforms and display a more aggressive neoplastic phenotype, J Clin Invest, 95, 1906, 10.1172/JCI117872
Jiffar, 2004, PKC-α mediates chemoresistance in acute lymphoblastic leukemia through effects on Bcl2 phosphorylation, Leukemia, 18, 505, 10.1038/sj.leu.2403275
Leirdal, 1999, Ribozyme inhibition of the protein kinase Ca triggers apoptosis in glioma cells, Br J Cancer, 80, 1558, 10.1038/sj.bjc.6690560
Kolch, 1993, Protein kinase Cα activates RAF-1 by direct phosphorylation, Nature, 364, 249, 10.1038/364249a0
Ruland, 2001, Bcl10 is a positive regulator of antigen receptor-induced activation of NF-κB and neural tube closure, Cell, 104, 33, 10.1016/S0092-8674(01)00189-1
El-Rayes, 2008, Protein kinase C: a target for therapy in pancreatic cancer, Pancreas, 36, 346, 10.1097/MPA.0b013e31815ceaf7
Friberg, 2005, Chemotherapy for advanced pancreatic cancer: past, present, and future, Curr Oncol Rep, 7, 186, 10.1007/s11912-005-0072-3
MacKeigan, 2005, Sensitized RNAI screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance, Nat Cell Biol, 7, 591, 10.1038/ncb1258
Cotteret, 2003, P21-activated kinase 5 (PAK5) localizes to mitochondria and inhibits apoptosis by phosphorylating bad, Moi Cell Biol, 23, 5526, 10.1128/MCB.23.16.5526-5539.2003
Cotteret, 2006, Nucleocytopiasmic shuttling of PAK5 regulates its antiapoptotic properties, Moi Cell Biol, 26, 3215, 10.1128/MCB.26.8.3215-3230.2006
Yamaguchi, 1995, Identification of a member of the MAPKKK family as a potential mediator of TGF-β signal transduction, Science, 270, 2008, 10.1126/science.270.5244.2008
Roberts, 1993, Physiological actions and clinical applications of transforming growth factor-β, Growth Factors, 8, 1, 10.3109/08977199309029129
Sakurai, 1998, TGF-β-activatedkinase 1 stimulates NF-κB activation by an NF-κB-inducing kinase-independent mechanism, Biochem Biophys Res Commun, 243, 545, 10.1006/bbrc.1998.8124
Sakurai, 1999, Functional interactions of transforming growth factor-β-activated kinase-1 with I-κB kinases to stimulate NF-ℐB activation, J Biol Chem, 274, 10641, 10.1074/jbc.274.15.10641
Arsura, 2003, Transient activation of NF-κB through a TAK1/IKK kinase pathway by TGF-β1 inhibits AP-1/SMAD signaling and apoptosis: implications in liver tumor formation, Oncogene, 22, 412, 10.1038/sj.onc.1206132
Sanna, 2002, IAP suppression of apoptosis involves distinct mechanisms: the TAK1/ JNK1 signaling cascade and caspase inhibition, Moi Cell Biol, 22, 1754, 10.1128/MCB.22.6.1754-1766.2002
Guo, 2001, A potential role of nuclear matrix-associated protein kinase CK2 in protection against drug-induced apoptosis in cancer cells, J Biol Chem, 276, 5992, 10.1074/jbc.M004862200
Ahmed, 2002, Joining the cell survival squad: an emerging role for protein kinase CK2, Trends Cell Biol, 12, 226, 10.1016/S0962-8924(02)02279-1
Tawfic, 2001, Protein kinase CK2 signal in neoplasia, Histol Histopathol, 16, 573
Desagher, 2001, Phosphorylation of bid by casein kinases I and II regulates its cleavage by caspase 8, Mol Cell, 8, 601, 10.1016/S1097-2765(01)00335-5
Li, 2002, Phosphorylation by protein kinase CK2: a signaling switch for the caspase-inhibiting protein ARC, Moi Cell, 10, 247, 10.1016/S1097-2765(02)00600-7
Faust, 2000, Antisense oligonucleotides against protein kinase CK2-αinhibit growth of squamous cell carcinoma of the head and neck in vitro, Head Neck, 22, 341, 10.1002/1097-0347(200007)22:4<341::AID-HED5>3.0.CO;2-3
Ravi, 2002, Sensitization of tumor cells to Apo2 ligand/trail-induced apoptosis by inhibition of casein kinase II, Cancer Res, 62, 4180
Ruzzene, 2002, Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HSI) in Jurkat cells, Biochem J, 364, 41, 10.1042/bj3640041